Skip to main content
SpringerLink
Log in

Managing cancer cachexia

  • Chapter
  • First Online:
Cancer Cachexia

  • 456 Accesses

Abstract

The European Palliative Care Research Collaboration (EPCRC) has developed evidence-based recommendations for the classification and treatment of cachexia in advanced cancer patients [1]. These treatment guidelines focus on patients with advanced cancer that are likely to suffer from refractory cachexia, a very serious condition especially as many of these patients are receiving palliative care and life expectancy is often short. Little cachexia-specific research has been done on this patient group and the EPCRC treatment guidelines had to consider whether research results taken from other disease stages could be applicable for patients with advanced and incurable disease with refractory cachexia [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Radbruch L, Elsner F, Trottenberg P, et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: European Palliative Care Research Collective; 2010.

    Google Scholar 

  2. Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol. 1999;8:133-141.

    Google Scholar 

  3. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52:72-91.

    Google Scholar 

  4. Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care-Part II: cachexia/anorexia and fatigue. J Palliat Med. 2006;9:409-421.

    Google Scholar 

  5. Topkan E, Yavuz AA, Ozyilkan O. Cancer cachexia: pathophysiologic aspects and treatment options. Asian Pac J Cancer Prev. 2007;8:445-451.

    Google Scholar 

  6. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:200-211.

    Google Scholar 

  7. Tazi E, Errihani H. Treatment of cachexia in oncology. Indian J Palliat Care. 2010;16:129-137.

    Google Scholar 

  8. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol. 2000;27:64-68.

    Google Scholar 

  9. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 1998;55:675-688.

    Google Scholar 

  10. Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X, Lopez-Soriano FJ. Cancer cachexia: a therapeutic approach. Med Res Rev. 2000;21:83-101.

    Google Scholar 

  11. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1993;10:14-18.

    Google Scholar 

  12. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40:695-700.

    Google Scholar 

  13. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2receptors. Pharmacol Ther. 1997;74:129-180.

    Google Scholar 

  14. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs. 2001;61:499-514.

    Google Scholar 

  15. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657-2662.

    Google Scholar 

  16. Meguid MM, Fetissov SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition. 2000;16:843-857.

    Google Scholar 

  17. Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Rossi Fanelli F. Cracking the riddle of cancer anorexia. Nutrition. 1996;12:706-710.

    Google Scholar 

  18. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer. 1990;67:33-36.

    Google Scholar 

  19. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14:65-73.

    Google Scholar 

  20. Genazzani AD, Strucchi C, Malavasi B, et al. Effects of cyproheptadine clorhydrate, a serotonin receptor antagonist, on endocrine parameters in weight-loss related amenorrhea. Gynecol Endocrinol. 2001;15:279-285.

    Google Scholar 

  21. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127-1132.

    Google Scholar 

  22. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993;11:762-767.

    Google Scholar 

  23. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990;66:1279-1282.

    Google Scholar 

  24. Feliui J, Gontalez-Baron M, Berrocal A, Ordonez A, Baron-Saura JM. Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? J Natl Cancer Inst. 1991;83:449-450.

    Google Scholar 

  25. Tchekmedyian NSN, Hickman MM, Siau JJ, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer. 1992;69:1268-1274.

    Google Scholar 

  26. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993;11:152-154.

    Google Scholar 

  27. Rowland KM, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1995;14:135-141.

    Google Scholar 

  28. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systematic review of randomised clinical trials. Ann Oncol. 2001;12:289-300.

    Google Scholar 

  29. Ottery FD, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Semin. Oncol. 1998;25(2 Suppl 6):35-44.

    Google Scholar 

  30. John M. Appetite Stimulants. In: Nicholson JR, Hofbauer kg, Anker SD, Inui A, eds. Pharmacotherapy of Cachexia. London:CRC Press; 2012:291-302.

    Google Scholar 

  31. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.

    Google Scholar 

  32. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci. 2001;2:551-560.

    Google Scholar 

  33. Garcia J, Boccia RV, Graham C, Kumor K, Polvino W. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol. 2007;25(June 20 Supplement):9133. ASCO website. www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=36473. Accessed July 17, 2012.

  34. Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachex Sarcopenia Muscle. 2010;1:169-176.

    Google Scholar 

  35. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology. 2006;130:1707-1720.

    Google Scholar 

  36. Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery. 2008;143:334-342.

    Google Scholar 

  37. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004;114:57-66.

    Google Scholar 

  38. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells. Circulation. 2004;109:2221-2226.

    Google Scholar 

  39. Wu R, Dong W, Zhou M, et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med. 2007;176:805-813.

    Google Scholar 

  40. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010;11:107-117.

    Google Scholar 

  41. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck. 2007;29:401-411.

    Google Scholar 

  42. Fearon KCH, Meyenfeldt Von MF, Moses AGW, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.

    Google Scholar 

  43. Fearon KCH. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44:1124-1132.

    Google Scholar 

  44. Palesty JA, Dudrick SJ. Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks. Surg Clin North Am. 2011;91:653-673.

    Google Scholar 

  45. Khan LUR, Ahmed J, Khan S, Macfie J. Refeeding syndrome: a literature review. Gastroenterol Res Pract. 2010;2011.

    Google Scholar 

  46. Solomon SM, Kirby DF. The refeeding syndrome: a review. J Parenter Enteral Nutr. 1990;14:90-97.

    Google Scholar 

  47. Sobotka L. Refeeding syndrome. In, Sobotka L, Allison SP, Furst P, Meier R, Pertkiewicz M, Soeters P, eds. Basics in clinical nutrition. 3rd edn. Prague: Galen; 2004:288-291.

    Google Scholar 

  48. Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer. 2001;42:143-157.

    Google Scholar 

  49. al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs. 2001;2:186-197.

    Google Scholar 

  50. Doyle CC, Kushi LHL, Byers TT, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2005;56:323-353.

    Google Scholar 

  51. Strasser F. Eating-related disorders in patients with advanced cancer. Support Care Cancer. 2003;11:11-20.

    Google Scholar 

  52. Ravasco P, Monteiro Grillo I, Camilo M. Cancer wasting and quality of life react to early individualized nutritional counseling. Clin Nutr. 2007;26:7-15.

    Google Scholar 

  53. Whitman MM. The starving patient: supportive care for people with cancer. Clin J Oncol Nurs. 2000;4:121-125.

    Google Scholar 

  54. Jenns K. Importance of nausea. Cancer Nurs. 1994;17:488-493.

    Google Scholar 

  55. Smith GF, Toonen TR. Primary care of the patient with cancer. Am Fam Physician. 2007;75:1207-1214.

    Google Scholar 

  56. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.

    Google Scholar 

  57. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991;83:613-620.

    Google Scholar 

  58. Koeller J, Aapro M, Gralla R, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 2002;10:519-522.

    Google Scholar 

  59. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2012;4:2297-2303.

    Google Scholar 

  60. McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw. 2007;5:35-43.

    Google Scholar 

  61. Eisenberg PP, Figueroa-Vadillo JJ, Zamora RR, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.

    Google Scholar 

  62. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9:675-678.

    Google Scholar 

  63. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.

    Google Scholar 

  64. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403-410.

    Google Scholar 

  65. Balducci L, Hardy CL, Lyman GH. Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol. 2001;8:170-287.

    Google Scholar 

  66. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.

    Google Scholar 

  67. Sullivan DH, Walls RC. Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients. J Am Geriatr Soc. 1994;42:471-477.

    Google Scholar 

  68. Sullivan DH. Impact of nutritional status on health outcomes of nursing home residents. J Am Geriatr Soc. 1995;43:195-196.

    Google Scholar 

  69. Sullivan DH, Walls RC, Bopp MM. Protein-energy undernutrition and the risk of mortality within one year of hospital discharge: a follow-up study. J Am Geriatr Soc. 1995;43:507-512.

    Google Scholar 

  70. Sullivan DH. The role of nutrition in increased morbidity and mortality. Clin Geriatr Med. 1995;11:661-674.

    Google Scholar 

  71. Thomas DR, Ashmen W, Morley JE, Evans WJ. Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci. 2000;55:M725-M734.

    Google Scholar 

  72. Bastow M, Rawlings J, Allison S. Benefits of supplementary tube feeding after fractured neck of femur: a randomised controlled trial. Br Med J. 1983;287:1589-1592.

    Google Scholar 

  73. Woo J, Ho SC, Mak YT, Law LK, Cheung A. Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. Age Ageing. 1994;23:40-48.

    Google Scholar 

  74. McMurtry CT, Rosenthal A. Predictors of 2-year mortality among older male veterans on a geriatric rehabilitation unit. J Am Geriatr Soc. 1995;43:1123-1126.

    Google Scholar 

  75. Yeh SS, Schuster MS. Cachexia And Wasting: A Modern Approach. Milan: Springer; 2006: 701-717.

    Google Scholar 

  76. Brinksma A, Huizinga G, Sulkers E, Kamps W, Roodbol P, Tissing W. Malnutrition in childhood cancer patients: A review on its prevalence and possible causes. Crit Rev Oncol Hematol. 2012;83:249-275.

    Google Scholar 

  77. Cole TJ. Assessment of growth. Best Pract Res Clin Endocrinol Metab. 2002;16:383-398.

    Google Scholar 

  78. Wilcox WD, Nieburg P, Miller DS. Failure to thrive. A continuing problem of definition. Clin Pediatr (Phila). 1989;28:391-394.

    Google Scholar 

  79. Jolley CD. Failure to thrive. Current Probl Pediatr Adolesc Health Care. 2003;33:183-206.

    Google Scholar 

  80. Lai J-S, Cella D, Goldman S. Anorexia/cachexia-related quality of life for children with cancer. Cancer. 2005;104:1531-1539.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

    Egidio Del Fabbro

  2. Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan

    Akio Inui

  3. Department of Internal Medicine, Cantonal Hospital, St Gallen, St. Gallen, Switzerland

    Florian Strasser

Authors
  1. Egidio Del Fabbro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akio Inui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florian Strasser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Egidio Del Fabbro .

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare

About this chapter

Cite this chapter

Del Fabbro, E., Inui, A., Strasser, F. (2012). Managing cancer cachexia. In: Cancer Cachexia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-910315-07-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-910315-07-1_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-910315-06-4

  • Online ISBN: 978-1-910315-07-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation